IS2294B - Samsetningar sem samanstanda af fósturblóðrauða og bakteríuinneitri og mögulega viðbótarhlutum fósturlifrar, þar sem fósturblóðrauðinn og mögulegir viðbótarhlutar fósturlifrar eru ekki fengnir úr mennskum vef - Google Patents

Samsetningar sem samanstanda af fósturblóðrauða og bakteríuinneitri og mögulega viðbótarhlutum fósturlifrar, þar sem fósturblóðrauðinn og mögulegir viðbótarhlutar fósturlifrar eru ekki fengnir úr mennskum vef

Info

Publication number
IS2294B
IS2294B IS7940A IS7940A IS2294B IS 2294 B IS2294 B IS 2294B IS 7940 A IS7940 A IS 7940A IS 7940 A IS7940 A IS 7940A IS 2294 B IS2294 B IS 2294B
Authority
IS
Iceland
Prior art keywords
fetal
additional components
hemoglobin
fetal hemoglobin
bacterial
Prior art date
Application number
IS7940A
Other languages
English (en)
Other versions
IS7940A (is
Inventor
Westphal Otto
Wälli Thierry
Gorczynski Reginald
Müller Silke
Mach Jean-Pierre
Hartmann Alfred
Bessler Wolfgang
Hofmann Petra
Zähringer Ulrich
Alexander Christian
Vor Dem Esche Ulrich
J. Ulmer Artur
Verdini Antonio
Original Assignee
Clinique La Prairie Research S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinique La Prairie Research S.A. filed Critical Clinique La Prairie Research S.A.
Publication of IS7940A publication Critical patent/IS7940A/is
Publication of IS2294B publication Critical patent/IS2294B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS7940A 2003-02-18 2005-07-18 Samsetningar sem samanstanda af fósturblóðrauða og bakteríuinneitri og mögulega viðbótarhlutum fósturlifrar, þar sem fósturblóðrauðinn og mögulegir viðbótarhlutar fósturlifrar eru ekki fengnir úr mennskum vef IS2294B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003687A EP1449535B1 (en) 2003-02-18 2003-02-18 Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components
PCT/EP2004/001553 WO2004073728A2 (en) 2003-02-18 2004-02-18 Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components

Publications (2)

Publication Number Publication Date
IS7940A IS7940A (is) 2005-07-18
IS2294B true IS2294B (is) 2007-10-15

Family

ID=32731533

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7940A IS2294B (is) 2003-02-18 2005-07-18 Samsetningar sem samanstanda af fósturblóðrauða og bakteríuinneitri og mögulega viðbótarhlutum fósturlifrar, þar sem fósturblóðrauðinn og mögulegir viðbótarhlutar fósturlifrar eru ekki fengnir úr mennskum vef

Country Status (20)

Country Link
US (1) US7968103B2 (is)
EP (2) EP1449535B1 (is)
JP (1) JP4619352B2 (is)
KR (1) KR101102481B1 (is)
CN (1) CN1750840A (is)
AT (1) ATE324903T1 (is)
AU (1) AU2004212703C1 (is)
BR (1) BRPI0407311B8 (is)
CA (1) CA2514485C (is)
DE (1) DE60304989T2 (is)
DK (1) DK1449535T3 (is)
ES (1) ES2263859T3 (is)
IL (1) IL169760A (is)
IS (1) IS2294B (is)
MX (1) MXPA05008797A (is)
NO (1) NO334003B1 (is)
NZ (1) NZ541417A (is)
PL (1) PL211789B1 (is)
RU (1) RU2366449C2 (is)
WO (1) WO2004073728A2 (is)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007103427A2 (en) * 2006-03-06 2007-09-13 Wang Xiang H Medical use of bilirubin and its structural analogues
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
WO2010006200A2 (en) * 2008-07-09 2010-01-14 Board Of Regents, The University Of Texas System Triggered release of drugs from polymer particles
WO2010123798A2 (en) 2009-04-20 2010-10-28 Galenbio, Inc. Compositions for transfection of biomolecules into cells
EP2789343A1 (en) * 2013-04-11 2014-10-15 Clinique La Prairie Novel hemoglobin-derived peptide based pharmaceutical compositions
EP3019186A4 (en) * 2013-07-12 2017-03-29 Patrick J. Casey Method for the harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473647A (en) * 1981-02-27 1984-09-25 Amf Inc. Tissue culture medium
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
EP0271521A4 (en) 1986-05-09 1989-11-14 Sloan Kettering Inst Cancer Lipopolysaccharide and natural factor compositions for anti-tumor therapy and method of treatment.
ATE126698T1 (de) 1989-06-30 1995-09-15 American Cyanamid Co Verwendung eines phagozytise-aktievierenden stoffes : lps oder il-2 zur herstellung eines arzneimittels zur behandlung von staphylococcus- aureus-infektionen bei kühen.
EP0472467A3 (en) 1990-08-20 1993-03-17 Chiba Flour Milling Co. Ltd. Lps-containing analgesics and veterinary analgesics
JPH0499481A (ja) * 1990-08-20 1992-03-31 Chiba Seifun Kk 新規細菌、新規ｌｐｓ、新規免疫機能活性化剤、新規動物用免疫機能活性化剤
JPH0690745A (ja) * 1990-08-20 1994-04-05 Chiba Seifun Kk Ｌｐｓ産生菌、ｌｐｓ、ｌｐｓを含む医薬及び動物薬
JPH04187640A (ja) * 1990-11-22 1992-07-06 Chiba Seifun Kk 経口・経皮免疫機能促進剤、動物用経口・経皮免疫機能促進剤
DE539610T1 (de) * 1991-10-26 1993-12-16 Torf Ets Verfahren und Zusammensetzung zur Bestimmung der Immunologischen Aktivität von aktiven Substanzen enthaltende Lösungen.
JP3199081B2 (ja) * 1992-11-13 2001-08-13 味の素株式会社 抗腫瘍剤
DE4338812A1 (de) * 1993-11-15 1995-05-18 Braun Melsungen Ag Verwendung von Lösungen von vernetztem Hämoglobin zur Bekämpfung des septischen und hämorrhagischen Schocks bei Säugetieren
US5648343A (en) * 1994-02-28 1997-07-15 The University Of Georgia Research Foundation Method for treating LPS-mediated disorders
US5580724A (en) * 1994-03-25 1996-12-03 Board Of Regents, The University Of Texas System Differential expansion of fetal stem cells in maternal circulation for use in prenatal genetic analysis
US20020065211A1 (en) * 1995-03-23 2002-05-30 Biopure Corporation Increasing function of organs having reduced red blood cell flow
DK0863866T3 (da) 1995-10-06 2001-06-11 Vertex Pharma Butyrat-prodrugs afledt af mælkesyre
WO1997025061A1 (en) * 1996-01-09 1997-07-17 Bristol-Myers Squibb Company De-myristolated lipopolysaccharide of gram-negative bacteria
EP0856592A1 (en) 1997-02-04 1998-08-05 N.V. Bekaert S.A. A coating comprising layers of diamond like carbon and diamond like nanocomposite compositions
JP4256938B2 (ja) * 1997-02-04 2009-04-22 ナムローゼ・フェンノートシャップ・ベーカート・ソシエテ・アノニム ダイヤモンド状カーボン及びダイヤモンド状ナノコンポジット組成物の層を有するコーティング物
RU2140283C1 (ru) * 1998-12-15 1999-10-27 Товарищество с ограниченной ответственностью "Биотех" Фармацевтический препарат на основе интерлейкина-2 (варианты)
EP2292657A1 (en) * 1999-11-12 2011-03-09 Baxter Biotech Technology S.A.R.L. Reduced side-effect hemoglobin compositions
EP2295968B1 (en) * 1999-12-03 2012-09-19 Baxter International Inc. Pyrogenicity test for use with automated immunoassay systems
US20010026800A1 (en) * 2000-01-07 2001-10-04 Michael Jacob G. Selective activation of a TH1 or TH2 lymphocyte regulated immune response
WO2002017965A1 (en) * 2000-08-28 2002-03-07 Akira Awaya Medicinal compositions
DE10103211C1 (de) * 2001-01-24 2002-07-18 Ursula Kastner Kulturmedium

Also Published As

Publication number Publication date
NZ541417A (en) 2008-08-29
BRPI0407311B8 (pt) 2021-11-30
KR20050111596A (ko) 2005-11-25
IS7940A (is) 2005-07-18
IL169760A (en) 2012-09-24
BRPI0407311A (pt) 2006-02-21
RU2005126141A (ru) 2006-01-27
KR101102481B1 (ko) 2012-01-05
WO2004073728A3 (en) 2004-10-07
WO2004073728A2 (en) 2004-09-02
EP1449535B1 (en) 2006-05-03
AU2004212703C1 (en) 2009-05-21
EP1449535A1 (en) 2004-08-25
PL378573A1 (pl) 2006-05-02
US20080075742A1 (en) 2008-03-27
US7968103B2 (en) 2011-06-28
NO20054087L (no) 2005-11-08
NO20054087D0 (no) 2005-09-02
DE60304989D1 (de) 2006-06-08
AU2004212703B2 (en) 2008-10-30
BRPI0407311B1 (pt) 2020-12-29
AU2004212703A1 (en) 2004-09-02
NO334003B1 (no) 2013-11-11
DE60304989T2 (de) 2007-03-29
EP1601371A2 (en) 2005-12-07
RU2366449C2 (ru) 2009-09-10
CN1750840A (zh) 2006-03-22
CA2514485C (en) 2013-11-05
PL211789B1 (pl) 2012-06-29
JP2006518350A (ja) 2006-08-10
DK1449535T3 (da) 2006-09-11
JP4619352B2 (ja) 2011-01-26
ES2263859T3 (es) 2006-12-16
CA2514485A1 (en) 2004-09-02
MXPA05008797A (es) 2006-05-25
ATE324903T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
SG163517A1 (en) Antiviral compounds and methods
MX2010001733A (es) Compustos de imidazo[1,2-a]pirazina para tratamiento de infecciones virales tales como hepatitis.
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
CY1109385T1 (el) Αναστολεις γυρασης και χρησεις αυτων
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
EP2322200A3 (en) Compositions and methods for the treatment of immune related diseases
MXPA05007462A (es) Derivados de pirrolopiridazina.
EP1492563A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF INFECTIONS WITH THE HERPES SIMPLEX VIRUS
MY144318A (en) Methods of treating hiv infection.
ZA200507070B (en) Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
NO20061911L (no) Immunogene sammensetninger
EA200600280A1 (ru) Композиции на основе производных липопептидных антибиотиков и способы их применения
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
WO2010075280A3 (en) Coumarin-based compounds for the treatment of alzheimer's disease and cancer
DE60307749D1 (de) Verwendung von Flavonoid-Derivaten zur Behandlung von atopischem Ekzem
AU2002303817A1 (en) Compositions and methods for treating or preventing convulsions or seizures
IS2294B (is) Samsetningar sem samanstanda af fósturblóðrauða og bakteríuinneitri og mögulega viðbótarhlutum fósturlifrar, þar sem fósturblóðrauðinn og mögulegir viðbótarhlutar fósturlifrar eru ekki fengnir úr mennskum vef
WO2006034001A3 (en) Methods of treating hiv infection
MX2021005423A (es) Macrolidos de 13 miembros sustituidos con c10-alquileno y usos de los mismos.
ATE442854T1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
WO2004110373A3 (en) Therapeutic vaccine compositions for the treatment of type 1 diabetes
PT1606233E (pt) Derivados de esteres lipidicos de nucleotidos
TW200503672A (en) 2-aminobenzoyl derivatives